Clinical trials: Metabolism
Diabetes, Nocturnal Hypoglycemia
Adjusting Insulin Delivery to Activity
Increased daytime activity in children and adolescents with type I diabetes is known to be associated with overnight hypoglycemia.
- Trial name
- AIDA (NCT02299479)
- Testing
- Dexcom G4 Platinum CGM, Activity monitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
ASCVD, Elevated Cholesterol
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
- Conditions
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
- Trial name
- ORION-8 (NCT03814187)
- Testing
- Inclisiran Sodium
- Where
- 238 sites in United States, Canada and 11 more
- Volunteers
- 3,275 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons
The purpose of this study is to compare two approaches to a diet and exercise-based weight loss program.
- Trial name
- SHINE (NCT00960414)
- Testing
- SHINE
- Where
- United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Obesity
Adaptive Goals and Interventions for Lifestyle Enhancement
Mobile obesity interventions have the potential to reach a diverse population in need; however, while effective, have not resulted in weight losses obtained in in-person interventions.
- Trial name
- AGILE (NCT04922216)
- Testing
- Core, Standard Diet Monitoring, Simplified Diet Monitoring
- Where
- United States
- Volunteers
- 759 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetic Nephropathy
Nephropathy In Type 2 Diabetes and Cardio-renal Events
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic…
- Trial name
- NID-2 (NCT00535925)
- Testing
- SoC therapy, irbesartan, ramipril
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- University of Campania Luigi Vanvitelli
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04504825
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Malnutrition
Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG "Rescue"
The purpose of this study is to determine: 1. Utility of urgent upper endoscopy in setting of dislodges (percutaneous endoscopic gastrostomy) PEG tube. 2.
- Trial name
- PEGRescue (NCT01119040)
- Testing
- Natural Orifice Translumenal Endoscopic Surgery
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Gaucher Disease
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the…
- Trial name
- NCT00376168
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 11 sites in United States, Canada and 6 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Overweight, Obese
Angiotensin II Blockade and Inflammation in Obesity
Overweight and obesity, which afflicts ~65% of the U.S. population and more than 1 billion people worldwide, increases the risk of developing hypertension.
- Conditions
- Overweight, Obese, Prehypertension, Hypertension
- Trial name
- ARB (NCT01684748)
- Testing
- Olmesartan medoxomil
- Volunteers
- 20 people
- Sponsor
- Virginia Polytechnic Institute and State University
Arthritis, Cancer
MoveStrong at Home: A Feasibility Study of a Model for Remote Delivery of Functional Strength and Balance Training Combined With Nutrition Education for Older Pre-frail Adults.
Sufficient muscle strength helps to get out of a chair and can prevent falls. Up to 30% of older adults experience age-related loss of muscle strength, which can lead to frailty and health instability.
- Conditions
- Arthritis, Cancer, Cardiovascular Diseases, Chronic Lung Disease
- Trial name
- NCT04663685
- Testing
- Exercise program, Nutrition education
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Waterloo
Type 2 Diabetes Mellitus
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis)…
- Trial name
- NCT01068717
- Testing
- Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hyperlipidemias
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent finding following transplantation and the…
- Trial name
- NCT04608474
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular Diseases, Diabetes
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk.
- Trial name
- DRIVE (NCT06046560)
- Testing
- SGLT2 inhibitor, GLP-1 RA, Education-First
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Obesity
Weight Discrimination and Poor Cardiovascular Health
People with obesity regularly experience discrimination on the basis of their body weight and such experiences are associated with increased risk for poor cardiovascular health.
- Trial name
- NCT05714696
- Testing
- Weight discrimination experience, Control experience
- Where
- United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Florida State University
HIV Infections
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen after switching their boosted PI to…
- Trial name
- NCT02097108
- Testing
- Raltegravir
- Where
- 3 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Nephrotic Syndrome, Edema
Amiloride in Nephrotic Syndrome
The AMILOR study compares treatment of edema in nephrotic syndrome with Amiloride vs. Furosemide.
- Conditions
- Nephrotic Syndrome, Edema, Sodium Retention
- Trial name
- AMILOR (NCT05079789)
- Testing
- Amiloride, Furosemide
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Osteopenia
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of…
- Trial name
- NCT00950950
- Testing
- Romosozumab
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Pompe Disease, Glycogen Storage Disease Type II (GSD II)
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
The primary objective of this study was to characterize the pharmacokinetics (PK) of alglucosidase alfa manufactured at the 4000 L scale in participants who had a confirmed diagnosis of Pompe disease.
- Trial name
- PAPAYA (NCT01410890)
- Testing
- alglucosidase alfa
- Where
- 12 sites in United States, Bulgaria and 4 more
- Volunteers
- 21 people
- Sponsor
- Genzyme, a Sanofi Company
Morbid Obesity
An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery
Bariatric surgery induce remarkable weight loss and improvement or resolution of type 2 diabetes. Obesity is the primary risk factor for type 2 diabetes, and 90% of all type 2 diabetics are obese.
- Trial name
- NCT02067585
- Testing
- Standardized Lipid meals
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University of Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.